Develops AI-powered point-of-care devices for early detection and prevention of skin disorders.
About
SciBase develops and commercializes Nevisense, a point-of-care platform that combines AI and advanced EIS technology to improve diagnostic accuracy in the detection of skin cancer and skin barrier alterations. This platform empowers healthcare professionals to enhance diagnostic accuracy, enable disease monitoring, and facilitate early intervention of skin cancer and skin disorders. SciBase aims to pioneer prediction and prevention in dermatology, ensuring proactive skin health management.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does SciBase do?
SciBase develops and commercializes Nevisense, a point-of-care platform that combines AI and advanced EIS technology to improve diagnostic accuracy in the detection of skin cancer and skin barrier alterations. This platform empowers healthcare professionals to enhance diagnostic accuracy, enable disease monitoring, and facilitate early intervention of skin cancer and skin disorders. SciBase aims to pioneer prediction and prevention in dermatology, ensuring proactive skin health management.
How much funding has SciBase raised?
SciBase has raised a total of $22M in funding. The most recent round on record is Post IPO.
Where is SciBase headquartered?
SciBase is headquartered in Stockholm, Sweden.
When was SciBase founded?
SciBase was founded in 1998.
What industry does SciBase operate in?
SciBase operates in Medical Technology, Dermatology, AI in Healthcare, Diagnostic Devices, Point-of-Care Testing, Skin Cancer Detection.